This study looks at providing ongoing access to daratumumab for people with multiple myeloma or smoldering multiple myeloma. Participants will continue to receive treatment if they have benefited in earlier studies. The goal is to gather long-term safety information while participants receive the treatment they need.
This is a Phase 3 trial, which means it looks at how well the treatment works and how safe it is. It is regulated by the FDA and aims to include about 500 participants.
Who can join
Anyone aged child to older adult can join, including men and women. Participants must be getting daratumumab or related treatments in certain previous studies and have not had disease progression. They should also agree to follow study rules and sign consent forms. The trial team will check who is eligible.
Condition
Multiple Myeloma
Age group
All ages
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will receive daratumumab through an IV or under the skin, either alone or with other treatments like pomalidomide or dexamethasone. Everyone in the study will receive the treatment, and no one will be left out. Some people who had daratumumab before may switch to a different method of receiving it.
Where
This trial is enrolling at 7 locations. Recruiting sites are listed first.
Barnes-jewish Hospital
St Louis, Missouri
Active Not Recruiting
Baylor University Medical Center
Dallas, Texas
Completed
Emory University
Atlanta, Georgia
Active Not Recruiting
Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg
New York, New York
Completed
Memorial Sloan Kettering Cancer Center
New York, New York
Completed
University of Miami Sylvester Cancer Center
Miami, Florida
Active Not Recruiting
University of Michigan Comprehensive Cancer Center
Professor and transplant specialist, UC Davis. Treats leukemia, lymphoma and multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.
Directs the Lipper Myeloma Center, Dana-Farber. Treats multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.